Search Results
Jul 02, 2025, 16:16 ET INOVIO Announces Proposed Public Offering
biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting
More news about: INOVIO Pharmaceuticals, Inc.
Jul 02, 2025, 15:59 ET MANAMED® LLC Achieves ISO 13485 Certification, Reinforcing Commitment to Quality and Global Expansion
the Medical Device Single Audit Program (MDSAP). "This certification is more than a regulatory benchmark—it's a reflection of our company's DNA," said Trevor Theriot, President and CEO of ManaMed. "We've always believed that innovation must be matched by integrity
More news about: ManaMed LLC
Jul 02, 2025, 11:00 ET Rosalind Franklin University Announces Doctor of Medical Science Degree
inquiry and excellence modeled by its namesake Dr. Rosalind Franklin, whose Photo 51 was crucial to solving the structure of DNA. Recognized for its research in areas including neuroscience, brain-related diseases, inherited disorders, diabetes, obesity, and gait and balance, RFU
More news about: Rosalind Franklin University of Medicine and Science
Jul 02, 2025, 11:00 ET SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response
chemotherapy, targeted therapy, immunotherapy, and combination therapies. The MTB model leverages shallow whole-genome sequencing (sWGS) of cell-free DNA to map the panoramic cancer genome. It integrates analysis of copy number aberrations (CNA), fragment size (FS), and seven protein biomarkers to deliver
More news about: SeekIn Inc
Jul 02, 2025, 10:30 ET Soft Tissue Repair Market to Hit $20.52 Billion by 2030--Driven by Regenerative Tech & Surgical Innovation | MarketsandMarkets™
DNA Diagnostics Market
More news about: MarketsandMarkets
Jul 02, 2025, 08:32 ET Pusan National University Researchers Develop Tool to Improve CRISPR Off-Target Predictions Using Genetic Variants
editing technologies like CRISPR-Cas9 have transformed biology, medicine, and agriculture, but concerns remain about unintended edits at off-target DNA sites. These off-target effects can cause harmful mutations and are difficult to predict, as they depend not only on the guide RNA but also on an organism's
More news about: Pusan National University
Jul 02, 2025, 08:31 ET O'Shaughnessy Ventures Awards Fellowship to Researcher Tackling the Biology of Aging
fellowship to design more precise genome engineering tools, improve whole-organism gene delivery systems and catalog rare, unusually potent variants of DNA repair enzymes. Together, these advances could pave the way for therapies that repair genetic damage, prevent cancer and slow age-related decline.
More news about: O'Shaughnessy Ventures
Jul 02, 2025, 07:00 ET MDA SPACE COMPLETES ACQUISITION OF SATIXFY COMMUNICATIONS
vision into an achievable mission – bringing to bear a one-of-a-kind mix of experience, engineering excellence and wide-eyed wonder that's been in our DNA since day one. For those who dream big and push boundaries on the ground and in the stars to change the world for the better, we'll take you there. For
More news about: MDA Space
Jul 01, 2025, 16:19 ET iconPCR™: Powering the Next Wave of Metagenomics and Microbiome Discovery
contain only picogram or femtogram levels of DNA, his laboratory has demonstrated iconPCR's ability to successfully amplify libraries from incredibly challenging samples: "We've been able to use a mock community down to 500 femtogram input DNA, amped with the iconPCR, and still able to recover
More news about: n6
Jul 01, 2025, 13:55 ET ISS National Lab Partners with AIAA to Expand ASCEND with Low Earth Orbit-Focused Sessions in 2025 and 2026
of scientists and engineers. At ASCEND, this year's finalists in the Genes in Space student research competition will present their proposals for DNA experiments to a panel of scientists and industry leaders for the opportunity to launch their project to the space station. The contest provides students
More news about: International Space Station National Lab
Jul 01, 2025, 13:29 ET LICORbio Expands Portfolio with Strategic Acquisition of SERVA Electrophoresis
SERVA's expansive electrophoresis products with our established imaging platforms, we're enabling more accurate, reproducible, and efficient protein, DNA, and RNA analysis workflows." "We're thrilled to welcome the SERVA team into LICORbio," said Bambi Reynolds, senior
More news about: LICORbio
Jul 01, 2025, 12:42 ET High Performance Manual Featured in LibraryBub Selection for July
Sjöfors ISBN: 978-1637351178 Resilience under Fire: from breakdown to breakthrough by Jochen Schwenk ISBN: 978-1637353806 Success DNA: mastering persistence in leadership and life by Alinka Rutkowska, Manuel R. Aragon,
More news about: LibraryBub
Jul 01, 2025, 10:30 ET Residual DNA Testing to Hit $370M by 2030 -- The Silent Guardian of Biologics Safety | MarketsandMarkets™
future, residual DNA testing is the new quality currency. It secures regulatory approvals, mitigates safety risks, and drives brand equity. Leaders who invest early in scalable, standardized DNA testing frameworks will define the next wave of biopharma growth. Residual DNA testing isn't an
More news about: MarketsandMarkets
Jul 01, 2025, 09:00 ET AIR Unveils New Production Facility to Accelerate eVTOL Deliveries in Response to Growing Demand
ensuring that AIR's rigorous safety, quality assurance, and operational standards are maintained throughout the production process. AIR's automotive-based DNA enables its Tier 1 suppliers to deliver proven and tested subsystems for assembly at the new site, streamlining operations and maintaining production
More news about: AIR
Jul 01, 2025, 09:00 ET Gene by Gene Supports Landmark Pharmacogenomics Trial to Personalize Prescribing in NHS Scotland
prescribed one or more of the 60 widely used medications in the NHS. With consent, participants will undergo a simple genetic test to analyse their DNA. The results – returned within days – will help doctors determine whether each patient is receiving the most suitable drug and dosage based on their
More news about: Gene by Gene
Jul 01, 2025, 08:56 ET Impact XM Shares Full Agenda, Featured Speakers, and Sponsors for 2025 Rethink Conference
organizations foster a culture of imagination and bold thinking. His presentation, "Embedding a Culture of Innovation & Creativity into Everyone's DNA," will explore how human traits like curiosity and intuition can give brands an edge in an AI-driven era. Closing out the day will be Julius
More news about: Impact XM
Jul 01, 2025, 08:00 ET Saisei Debuts Foundation Collection for Pre-Fall 2025
Body Language, a curated edit of seamless intimates, performance layers, and refined lifestyle essentials. Designed from the core of Saisei's DNA this collection expresses freedom through comfort, unseen innovation, and intention. Saisei's advanced seamless design approach prioritizes body
More news about: SAISEI
Jul 01, 2025, 07:30 ET Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions
thicker plaques and lesions. This treatment approach avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging drugs and other phototherapy that are dependent on ultraviolet exposure. Combined with photoactivation, hypericin has demonstrated significant
More news about: SOLIGENIX, INC.
Jul 01, 2025, 07:00 ET Green Sands Equity Welcomes Eric Sarasin as New Partner
long-term, ethical capital in a fast-changing global economy. Eric was born into a successful entrepreneurial family and has the corresponding "DNA". At Bank Sarasin, he held various management positions in numerous business areas and developed the formerly family-owned bank into one of the leading
More news about: Green Sands Equity
Jul 01, 2025, 03:00 ET Hemispherian Receives U.S. FDA Orphan Drug Designation for GLIX1 for the Treatment of Malignant Glioma
regulatory pathwaysAbout GLIX1 and Hemispherian GLIX1 is a first-in-class small-molecule therapeutic targeting DNA repair vulnerabilities in cancer cells. Hemispherian's proprietary GLIX platform enables the selective elimination of cancer cells with minimal impact
More news about: Hemispherian AS
Jun 30, 2025, 15:00 ET Alltius Launches Voice AI agents & workflows for Insurance, Banking & Financial Services
Voice AI agents differentiates itself through five core capabilities: Financial Services DNA: Pre-trained on insurance claims, loan processing, and wealth management conversations with deep domain knowledge of financial terminology and workflows.Direct
More news about: Alltius Inc.
Jun 30, 2025, 12:09 ET Rapid Diagnostics Market to Reach $24.28 Billion by 2032, Growing at a CAGR of 6.6% from 2025, Says Meticulous Research®
and secure patient data management through blockchain technology Advanced Lateral Flow Technology: Implementation of DNA nanostructures replacing traditional antibodies in lateral flow assays, offering higher binding affinity and specificity for target antigens while reducing
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:15 ET Protein Expression Market to Reach $5 Billion by 2032, Growing at a CAGR of 7.6% from 2025, Says Meticulous Research®
therapeutic and industrial sectors. Market leaders are investing substantially in mammalian cell expression technologies, advanced recombinant DNA systems, and sustainable protein production methods, establishing manufacturing capabilities that can deliver high-yield, high-quality protein synthesis
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 11:00 ET Whole Genome Sequencing Market to Reach $8.35 Billion by 2032, Growing at a CAGR of 15.4% from 2025, Says Meticulous Research®
comprehensive market research report titled "Whole Genome Sequencing Market Size, Share, Forecast, & Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball) Application, End User – Global Forecast to 2032",
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 10:49 ET Merrell Advances Running Innovation with the Launch of the High-Tech ProMorph Hybrid
with the debut of the ProMorph, an all-terrian hybrid built with responsive cushioning and confident grip across any surface. The ProMorph merges the DNA of an elite road racer with the technicality of a trail shoe, making it Merrell's most well-rounded hybrid to date.
More news about: Merrell